April 23rd, 2025 – Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular diagnostics firm specializing in early cancer detection, is expanding its clinical and commercial ambitions beyond colorectal cancer as it accelerates efforts to tackle pancreatic cancer — one of the most lethal and underdiagnosed malignancies.
Post-Listing Momentum and Market Confidence
The company entered 2025 on firm footing, having completed all Nasdaq listing requirements, a move seen by analysts as a confidence signal to institutional investors and a foundation for broader U.S. market activity. Mainz’s growth trajectory has been further validated by a 33% year-over-year rise in lab-partner revenue across Europe, fueled by continued adoption of its flagship test, ColoAlert®, a non-invasive colorectal screening solution.
Colorectal Trial Results Impress
Mainz’s eAArly DETECT 2 trial, a follow-up to its landmark clinical study, has reported preliminary data that could reshape diagnostic standards:
- 97% sensitivity for colorectal cancer
- 82% for advanced precancerous lesions
- 100% for high-grade dysplasia
The results underpin the company’s assertion that accessible, at-home screening can rival the accuracy of more invasive procedures.
Targeting a Critical Gap: Pancreatic Cancer
Looking beyond colorectal screening, Mainz has initiated development of a blood-based pancreatic cancer test in partnership with Liquid Biosciences. Early-phase results suggest 95% sensitivity and 98% specificity—a compelling proposition in a field where early detection tools remain scarce.
Should the test withstand further clinical scrutiny, Mainz could gain first-mover advantage in a high-need diagnostic segment.
Strategic Alliances Bolster U.S. Entry
Mainz’s ambitions are supported by heavyweight collaborators. Thermo Fisher Scientific is assisting in advancing next-generation colorectal diagnostics, while Quest Diagnostics is underwriting a U.S.-based clinical trial — a critical step toward FDA clearance for ColoAlert®.
CEO Outlook
“We’re entering a transformative chapter,” said Guido Baechler, CEO of Mainz Biomed. “Our approach to precision diagnostics positions us to lead a new era of cancer detection—where accuracy, accessibility, and innovation converge.”
With an expanding biomarker platform, robust trial pipeline, and strategic global partners, Mainz Biomed is fast establishing itself as a significant player in the competitive oncology diagnostics market.
For more information, visit mainzbiomed.com
